MESO
MesoblastMESO
MESO
About: Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
Employees: 73
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
89% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 9
53% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 15
12% more funds holding
Funds holding: 60 [Q4 2024] → 67 (+7) [Q1 2025]
9% more call options, than puts
Call options by funds: $6.22M | Put options by funds: $5.69M
0.04% more ownership
Funds ownership: 0.26% [Q4 2024] → 0.3% (+0.04%) [Q1 2025]
20% less capital invested
Capital invested by funds: $59.9M [Q4 2024] → $48M (-$11.9M) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for MESO.
Financial journalist opinion
Based on 4 articles about MESO published over the past 30 days
Positive
Zacks Investment Research
1 week ago
Mesoblast Limited (MESO) Is Up 40.59% in One Week: What You Should Know
Does Mesoblast Limited (MESO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Neutral
GlobeNewsWire
1 week ago
Successful Commercial Launch of Ryoncil®
NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue from sales of Ryoncil® (remestemcel-L-rknd) through the first quarter post product launch. Ryoncil® is the first and only FDA approved mesenchymal stromal cell (MSC) product in the Unites States and became commercially available for purchase on March 28, 2025, within one quarter of receiving FDA approval for treatment of steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children.
Positive
Benzinga
4 weeks ago
Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor
On Monday, Mesoblast Ltd. MESO announced alignment with the U.S. Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor (rexlemestrocel-L) for ischemic heart failure with reduced ejection fraction (HFrEF) and inflammation.
Neutral
GlobeNewsWire
4 weeks ago
Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure
NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic heart failure with reduced ejection fraction (HFrEF) and inflammation.
Neutral
GlobeNewsWire
1 month ago
Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation, and label extension for Ryoncil® (remestemcel-L-rknd) in adults with steroid refractory acute graft versus host disease (SR-aGvHD).
Neutral
GlobeNewsWire
2 months ago
FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®
NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received seven years of orphan-drug exclusive approval from U.S. Food and Drug Administration (FDA) for Ryoncil® (remestemcel-L) for treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age and older.
Positive
Seeking Alpha
2 months ago
Bullish On Mesoblast: Shifting To Commercial Stage With Ryoncil Approval And Revascor Trials
MESO's Off-the-shelf MSC/MPC platform treats severe inflammatory diseases without donor–recipient matching. This alleviates the typical need for immunosuppression. The FDA recently approved Ryoncil, which achieved as much as 70% response in pediatric SR-aGVHD patients. And it has adult SR-aGVHD and Crohn's Phase 3 trials underway. MESO's Revascor is also in trials for chronic low back pain and heart failure, and its accelerated BLA could position it as another revenue vertical in the next couple of.
Neutral
GlobeNewsWire
3 months ago
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third quarter ended March 31, 2025.
Neutral
GlobeNewsWire
3 months ago
Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Lyn Cobley to its Board of Directors. Ms. Cobley has been a global leader in the financial services industry with over 30 years' experience in senior positions at international and domestic banks. Ms. Cobley has served as CEO of Westpac Institutional Bank, Group Treasurer of Commonwealth Bank of Australia, and held senior roles at Barclays Capital and Citibank Limited.
Neutral
GlobeNewsWire
3 months ago
Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives
NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has continued to expand coverage for Ryoncil® (remestemcel-L), the first mesenchymal stromal cell (MSC) therapy approved by U.S. Food and Drug Administration (FDA) for any indication, to 104 million US lives insured by government and commercial payers.
Charts implemented using Lightweight Charts™